The University of Chicago Header Logo

Connection

Michael Charlton to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Michael Charlton has written about Treatment Outcome.
Michael Charlton
Connection Strength
1.458
Treatment Outcome
  1. Living Donor Liver Transplantation in the United States: Evolution of Frequency, Outcomes, Center Volumes, and Factors Associated With Outcomes. Liver Transpl. 2021 07; 27(7):1019-1031.
    View in: PubMed
    Score: 0.083
  2. Liver Transplantation of HCV-viremic Donors Into HCV-negative Recipients in the United States: Increasing Frequency With Profound Geographic Variation. Transplantation. 2021 06 01; 105(6):1285-1290.
    View in: PubMed
    Score: 0.082
  3. International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation. 2018 05; 102(5):727-743.
    View in: PubMed
    Score: 0.067
  4. Alcoholic Liver Disease and Liver Transplantation. Clin Liver Dis. 2016 08; 20(3):521-34.
    View in: PubMed
    Score: 0.059
  5. Liver Transplantation for Alcoholic and Nonalcoholic Fatty Liver Disease: Pretransplant Selection and Posttransplant Management. Gastroenterology. 2016 06; 150(8):1849-62.
    View in: PubMed
    Score: 0.057
  6. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int. 2015 Nov; 35(11):2433-41.
    View in: PubMed
    Score: 0.055
  7. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep; 149(3):649-59.
    View in: PubMed
    Score: 0.054
  8. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015 Jan; 148(1):108-17.
    View in: PubMed
    Score: 0.052
  9. Improving long-term outcomes after liver transplantation. Clin Liver Dis. 2014 Aug; 18(3):717-30.
    View in: PubMed
    Score: 0.051
  10. Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review. Liver Transpl. 2013 Dec; 19(12):1311-7.
    View in: PubMed
    Score: 0.049
  11. How important is acute cellular rejection? Liver Transpl. 2013 Nov; 19 Suppl 2:S9-13.
    View in: PubMed
    Score: 0.049
  12. Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation. Liver Transpl. 2012 Jul; 18(7):803-10.
    View in: PubMed
    Score: 0.044
  13. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011 Oct; 141(4):1249-53.
    View in: PubMed
    Score: 0.041
  14. Pretransplant serum troponin levels are highly predictive of patient and graft survival following liver transplantation. Liver Transpl. 2010 Aug; 16(8):990-8.
    View in: PubMed
    Score: 0.039
  15. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant. 2010 Jun; 10(6):1420-7.
    View in: PubMed
    Score: 0.038
  16. Antibody-based immunosuppression following liver transplantation: the plot thickens. Am J Transplant. 2010 Mar; 10(3):445-6.
    View in: PubMed
    Score: 0.038
  17. Obesity, hyperlipidemia, and metabolic syndrome. Liver Transpl. 2009 Nov; 15 Suppl 2:S83-9.
    View in: PubMed
    Score: 0.037
  18. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008 Nov; 8(11):2426-33.
    View in: PubMed
    Score: 0.034
  19. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant. 2008 Mar; 8(3):667-72.
    View in: PubMed
    Score: 0.033
  20. Impact of obesity on treatment of chronic hepatitis C. Hepatology. 2006 Jun; 43(6):1177-86.
    View in: PubMed
    Score: 0.029
  21. Retransplantation for HCV--the view through a broken crystal ball. Liver Transpl. 2005 Apr; 11(4):382-3.
    View in: PubMed
    Score: 0.027
  22. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl. 2004 Sep; 10(9):1120-30.
    View in: PubMed
    Score: 0.026
  23. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 02 08; 390(6):497-509.
    View in: PubMed
    Score: 0.025
  24. Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis. Viruses. 2023 09 29; 15(10).
    View in: PubMed
    Score: 0.024
  25. Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis. 2003 Aug; 7(3):585-602.
    View in: PubMed
    Score: 0.024
  26. Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study. Hepatology. 2023 10 01; 78(4):1223-1239.
    View in: PubMed
    Score: 0.024
  27. Relatively Poor Long-term Outcomes Following Liver Transplantation for NASH in the United States. Transplantation. 2022 10 01; 106(10):2006-2018.
    View in: PubMed
    Score: 0.022
  28. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl. 2002 Apr; 8(4):362-9.
    View in: PubMed
    Score: 0.022
  29. Hepatitis C infection in liver transplantation. Am J Transplant. 2001 Sep; 1(3):197-203.
    View in: PubMed
    Score: 0.021
  30. Impact of nutritional status on outcomes after liver transplantation. Transplantation. 2000 Nov 15; 70(9):1347-52.
    View in: PubMed
    Score: 0.020
  31. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemp Clin Trials. 2020 01; 88:105889.
    View in: PubMed
    Score: 0.019
  32. Simultaneous heart, liver and kidney transplantation: A viable option for heart failure patients with multiorgan failure. J Heart Lung Transplant. 2019 09; 38(9):997-999.
    View in: PubMed
    Score: 0.018
  33. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era. Liver Transpl. 2019 04; 25(4):598-609.
    View in: PubMed
    Score: 0.018
  34. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. J Hepatol. 2019 01; 70(1):133-141.
    View in: PubMed
    Score: 0.017
  35. Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. World J Gastroenterol. 2018 Mar 28; 24(12):1321-1331.
    View in: PubMed
    Score: 0.017
  36. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2017 03; 15(3):421-430.e6.
    View in: PubMed
    Score: 0.015
  37. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol. 2016 10; 1(2):122-132.
    View in: PubMed
    Score: 0.015
  38. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015 Dec 31; 373(27):2618-28.
    View in: PubMed
    Score: 0.014
  39. Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl. 2015 Feb; 21(2):248-57.
    View in: PubMed
    Score: 0.013
  40. Comparative effectiveness of telaprevir-based triple therapy in patients with chronic hepatitis C. Mayo Clin Proc. 2014 May; 89(5):595-601.
    View in: PubMed
    Score: 0.013
  41. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013 Jul; 19(7):690-700.
    View in: PubMed
    Score: 0.012
  42. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant. 2013 Feb; 13(2):363-8.
    View in: PubMed
    Score: 0.011
  43. Introduction to the genetics and biology of interleukin-28B. Hepatology. 2012 Jul; 56(1):361-6.
    View in: PubMed
    Score: 0.011
  44. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011 Dec; 17(12):1394-403.
    View in: PubMed
    Score: 0.011
  45. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl. 2011 May; 17(5):528-38.
    View in: PubMed
    Score: 0.010
  46. Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C. J Clin Gastroenterol. 2010 Sep; 44(8):e178-85.
    View in: PubMed
    Score: 0.010
  47. Combined heart and liver transplantation: a single-center experience. Transplantation. 2009 Jul 27; 88(2):219-25.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.